HikalNSE:HIKAL +4.78%72 OCF Yield % is 10.01 as of Jul. 13, 2026. GuruFocus rates NSE:HIKAL with a GF Score™ of 72/100 and a GF Value™ of ₹276.90 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Hikal ranks better than 79.15% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Hikal OCF Yield % Related Terms
Hikal OCF Yield % Historical Data
* Premium members only.
The historical data trend for Hikal's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hikal's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikal OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikal's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Hikal's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikal (NSE:HIKAL) has a OCF Yield % of 10.01 as of Jul. 13, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Hikal and its competitors. Over the past decade, Hikal's OCF Yield % has ranged from 10.01 to 10.01. According to the industry distribution chart, Hikal ranks #210 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 20.9%.
Is Hikal's OCF Yield % too high?
Hikal's current OCF Yield % is 10.01. Over the past 10 years, this metric has ranged from a low of 10.01 to a high of 10.01. The Drug Manufacturers industry median OCF Yield % is 3.53. Hikal's value of 10.01 is 183.6% above this industry median. Based on the distribution chart, Hikal ranks #210 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hikal has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikal's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikal ranks #210 out of 1007 companies for OCF Yield %. This places Hikal in the top 21% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 3.53. Hikal's value of 10.01 is 183.6% above this benchmark. Historically, Hikal's own OCF Yield % has ranged from 10.01 to 10.01 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.53, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikal's current OCF Yield % of 10.01 is 183.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Hikal and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikal's current OCF Yield % is 10.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikal stock overvalued right now?
Based on GuruFocus' analysis, Hikal (NSE:HIKAL) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹276.90, compared to a current price of ₹244.75 — trading 11.6% below its estimated fair value. The current OCF Yield % is 10.01 and 183.6% above the Drug Manufacturers industry median of 3.53. Hikal's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Hikal (NSE:HIKAL), the current OCF Yield % is 10.01 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikal (NSE:HIKAL) Overvalued in 2026?
Based on GuruFocus' analysis, Hikal stock appears to be undervalued.
The current stock price of ₹244.75 is trading 11.6% below its estimated GF Value™ of ₹276.90.
GuruFocus considers Hikal to be Modestly Undervalued.
Key valuation signals for NSE:HIKAL:
OCF Yield %: 10.01
GF Value™: ₹276.90 vs. price of ₹244.75 (11.6% below fair value)
Industry Position: 183.6% above the Drug Manufacturers median (#210 of 1007)
No single metric tells the full story. See the NSE:HIKAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikal Ltd manufactures chemical intermediates, specialty chemicals, active pharmaceutical ingredients, and contract research activities. Its products are distributed to the pharmaceutical, biotech, agrochemical, and specialty chemical industries. Its segments include Crop Protection and Pharmaceuticals. The majority of the revenue is derived from the pharmaceutical segment.
72GF Score
Get the complete analysis for NSE:HIKAL
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:HIKAL has been successfully added to your 
